Apoptosis Inhibitor

Morroniside (Standard) is the analytical standard of Morroniside. This product is intended for research and analytical applications. Morroniside has neuroprotective effect by inhibiting neuron apoptosis and MMP2/9 expression.

HMGB1-IN-2 (compound 15) is an inhibitor of highly conserved nuclear protein (HMGB1), showing NO inhibitory effect with IC₅₀ value of 20.2 μM in RAW264.7 cells. HMGB1-IN-2 (30 μM) decreases the level of IL-1 β, TNF-α, caspase-1 p20, inhibits the phosphorylation of NF-κB p65, exhibits anti-apoptotic activity. HMGB1-IN-2 (15 mg/kg; ip) relives kidney injury in septic acute kidney injury mouse. HMGB1-IN-2 inhibits Huh7 cells and A549 cells with IC₅₀s of 77.0 μM, and 82.0 μM, respectively.

Astringin (trans-Astringin) (Standard) is the analytical standard of Astringin (HY-N4093). This product is intended for research and analytical applications. Astringin (trans-Astringin) is an orally active natural flavonoid compound. Astringin can inhibit the production of oxidative stress, inflammatory factors, etc. Astringin has multiple activities such as anti-oxidation, anti-inflammation, and anti-apoptosis. Astringin is also an inhibitor of ferroptosis. Astringin can be used in the research of diseases such as acute lung injury.

2-(3-Hydroxyphenyl-2,4,6-d₃)acetic-2,2-d₂ acid is the deuterium labeled 3-Hydroxyphenylacetic acid (HY-W001083). 3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders.

MAO-B-IN-26 (Compound IC9) is a MAO-B and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease.

Hepatoprotective agent-1 (compound 1b) is a hepatoprotective agenrt. Hepatoprotective agent-1 shows anti-inflammatory, antiapoptotic and antifibrotic effects.

Negundoside is an iridoid glycoside compound. Negundoside exhibits hepatoprotective effects, reduces ROS, lipid peroxidation and intracellular calcium ion levels, and prevents the decrease of mitochondrial membrane potential (MMP) and apoptosis (apoptosis). Negundoside has neuroprotective effects, improves behavioral deficits, alleviates oxidative damage, and ameliorates cerebral infarction. Negundoside also possesses antibacterial and antiparasitic activities.

Multitarget AD-IN-3 is a brain-penetrant neuroprotective agent. Multitarget AD-IN-3 can selectively inhibit MAO-B with an IC₅₀ of 4.42 μM and a SI of 18.12. Multitarget AD-IN-3 can eliminate ROS. Multitarget AD-IN-3 Multitarget AD-IN-3 can inhibit Aβ_1-42 self-aggregation and can reverse Aβ_1-42-induced mitochondrial membrane depolarization and inhibit apoptosis. Multitarget AD-IN-3 can be used for the research of neurological disease, such as Alzheimer’s disease.

WYRGRLC is a type II collagen-targeting peptide. WYRGRLC specifically binds to type II collagen α1 in articular cartilage in a sequence-dependent manner. WYRGRLC inhibits the binding of WYRGRL-displaying phage (C1-3) to articular cartilage in a sequence-specific manner. WYRGRLC can act as a retention enhancer to improve the cartilage-targeting ability of polymeric nanoparticles and liposomal nanoplatforms, facilitating the delivery of Rapamycin (HY-10219) to chondrocytes. WYRGRLC can be used in studies related to osteoarthritis.

Oblimersen sodium scrambled negative control is the sequence scrambled negative control of Oblimersen sodium.

K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase.

Diallyl tetrasulfide is an orally active diallyl tetrasulfide. Diallyl tetrasulfide ameliorates cadmium-induced changes in acetylcholinesterase and adenosine triphosphatase activities as well as oxidative stress injury in the brain of rats. Diallyl tetrasulfide inhibits lipid peroxidation in rat liver microsomes. Diallyl tetrasulfide ameliorates cadmium-induced oxidative liver injury in rats. Diallyl tetrasulfide protects cells against cadmium-induced loss of cell viability, reduces apoptosis rate and ROS production. Diallyl tetrasulfide is applicable to research related to cadmium-induced neurotoxicity and cadmium-induced oxidative liver injury.

3-Hydroxyhericenone F is a neuroprotective agent. Hydroxyhericenone F protects cells against NaN₃-induced toxicity, ultrastructural changes, and alterations in mitochondrial respiratory chain complexes. 3-Hydroxyhericenone F decreases intracellular ROS and calcium levels, increases mitochondrial membrane potential and ATP levels, attenuates NaN₃ -induced changes in apoptosis-related proteins, and protects neuronal cells from endoplasmic reticulum stress-dependent cell death. 3-Hydroxyhericenone F can be used in research related to cancer, Alzheimer's disease, and neurodegenerative diseases.

JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC₅₀ of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable.

K20 is a potent and selective KRas G12C inhibitor with an IC₅₀ of 1.16 µM. K20 shows anticancer activity in H358 cells (IC₅₀= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity.

Z-Asp(OMe)-Gln-Met-Asp(OMe)-FMK is an inhibitor for caspase-3, and inhibits Dihydroartemisinin (HY-N0176) and Dictamnine (HY-N0849) co-induced apoptosis.

Tilmicosin (phosphate) (Standard) is the analytical standard of Tilmicosin (phosphate). This product is intended for research and analytical applications. Tilmicosin (LY-177370) phosphate is an orally active calcium channel antagonist and macrolide antibiotic with antimicrobial activity. Tilmicosin phosphate mainly acts on the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. Tilmicosin phosphate is effective in the treatment of respiratory diseases in livestock such as cattle, sheep and pigs. In addition, Tilmicosin phosphate has immunomodulatory and anti-inflammatory effects.

OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739).

DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. DD0-2363 inhibits cells proliferation and induces apoptosis in acute myeloid leukemia cells. DD0-2363 has antitumor activity and can be used in the research of acute myeloid leukemia.

Kukoamine B (Standard) is the analytical standard of Kukoamine B. This product is intended for research and analytical applications. Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis.